France· FR:62924833
VINORELBINE ARROW 10 mg/mL, solution à diluer pour perfusion
A vinorelbine product containing tartrate de vinorelbine, registered in France by EUGIA PHARMA (MALTA) (MALTE). The same ATC class is registered in 18 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Vinorelbine is registered in 18 of 19 countries.
Countries holding a registration under ATC L01CA04 (vinorelbine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 11 of them publish a price we can compare per daily dose
Vinorelbine · ATC L01CA04
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vinorelbine costs, country by country.
Normalised to the WHO defined daily dose (18 mg), the median price runs from $23.93 in France to $49.84 in Switzerland — a ×2.1 gap.
- France: $23.93 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Vinorelbine · price per daily dose (18 mg)
USD · FX 28 Sept 2026
- CH Switzerland$49.84
- IT Italy$38.71
- FR France$23.93
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TARTRATE DE VINORELBINE
- Manufacturer
- EUGIA PHARMA (MALTA) (MALTE)
- Country
- France (FR)
- ATC code
- L01CA04
- ATC class
- Vinorelbine
- Defined daily dose
- 18 mg, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009573819981 flacon(s) en verre de 1 ml
- cip1334009573821311 flacon(s) en verre de 5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
536 interactions on record for vinorelbine.
Graded by severity as the source publishes them — 60 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vinorelbine · interactions on record
536 records
- 60 severe
- 307 moderate
- 17 minor
- 152 info
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- KetoconazoleH02CA03severe
- ErythromycinJ01FA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vinorelbine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsNavirel 10 mg/ml, concentraat voor oplossing voor infusieMedac Gesellschaft für klinische Spezialpräparate mbH
- CzechiaNAVELBINEPIERRE FABRE MEDICAMENT, Lavaur
- FinlandNavelbinePierre Fabre Pharma Norden AB
- United KingdomNavelbine 10mg/1ml concentrate for solution for infusion vialsPierre Fabre Ltd
- SwedenNavelbine 20 mg Kapsel, mjukPierre Fabre Medicament
- SpainNAVELBINE 10 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSIONPierre Fabre Iberica S.A.
- PolandNavelbinePierre Fabre Medicament
- SwitzerlandNavelbine 20 mg, WeichkapselnPierre Fabre Pharma SA
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Eberelbin, Navelbine
- Belgium · Vinorelbin Eugia, Vinorelbine Accord Healthcare
- Bulgaria · Винорелбин "ебеве"
- Cyprus · Navirel, Vinorelbine Accord
- Czechia · Navelbine, Navelbine Oral
- Germany · Bendarelbin, Navelbine
- Denmark · Navelbine, Navirel
- Estonia · Navelbine, Vinorelbin Ebewe
- Spain · Navelbine, Vinorelbina Accord
- Finland · Navelbine, Vinorelbin Ebewe
- United Kingdom (Northern Ireland) · Navelbine, Vinorelbine
- Greece · Navelbine, Zaolin
- Croatia · Vinorelsin
- Hungary · Vinorelbin Sandoz
- Ireland · Navelbine, Vinorelbine Accord
- Iceland · Navelbine, Navirel
- Italy · Navelbine, Vinorelbina Accord
- Lithuania · Navelbine, Vinorelbin Ebewe
- Luxembourg · Vinorelbin Ab, Vinorelbin Eugia
- Latvia · Vinorelbine Accord
- Malta · Vinorelbine Lotus, Vinorelbine Medac
- Netherlands · Navelbine, Navirel
- Norway · Navelbine, Navirel
- Poland · Navelbine, Navirel
- Portugal · Navelbine, Vinorrelbina
- Romania · Navelbine, Vinorelbin Teva
- Sweden · Navelbine, Navirel
- Slovenia · Vinorelbin Accord, Vinorelbin Sandoz
- Slovakia · Navelbine, Navelbine Oral
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/29bf9aa0-0284-4b47-8bcb-ae24f3c6a4a6 GET /v1/drugs/29bf9aa0-0284-4b47-8bcb-ae24f3c6a4a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62924833",
"date_amm": "2008-10-09",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "TARTRATE DE VINORELBINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about vinorelbine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.